Physician profile
Pinki Patel
NPI 1760496269
$9,775.51
in general payments reported to CMS, 2019-2025
25 companies · $2,554 in 2025
The $2,554 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $496 · 2022: $1,809 · 2023: $2,611 · 2024: $2,306 · 2025: $2,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,316 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,315.57 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,621.50 | 2021-2025 | Enbrel, Krystexxa, Evenity |
| Ucb, INC. | $1,433.96 | 2022-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,220.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,037.89 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,006.38 | 2021-2025 | |
| Janssen Biotech, INC. | $813.89 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Glaxosmithkline, LLC. | $485.91 | 2022-2025 | Benlysta |
| Pfizer INC. | $474.32 | 2022-2025 | |
| Lilly USA, LLC | $363.85 | 2022-2025 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $244.67 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.59 | 2022-2024 | Ofev, Cyltezo |
| Radius Health, INC. | $158.24 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $107.77 | 2022-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $95.92 | 2021-2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $91.68 | 2022-2025 | Strensiq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $87.97 | 2021-2023 | Lupkynis |
| Sandoz INC. | $62.93 | 2023-2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $44.85 | 2025 | Cuvitru |
| Ani Pharmaceuticals, INC. | $44.06 | 2023-2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $31.95 | 2024 | |
| Fresenius Kabi USA, LLC | $25.02 | 2023 | |
| Genentech USA, INC. | $24.58 | 2024 | Actemra |
| Bioventus LLC | $22.36 | 2023 | Gelsyn-3 |
| Sobi, INC | $19.58 | 2024 | |
| Depuy Synthes Sales INC. | $14.59 | 2024 | Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinki Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.